Compare Tango Therapeutics Inc. (TNGX) vs Viasat (VSAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Viasat — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Viasat trades at $60.7 (market cap $9.21B). The key difference: Viasat is far larger — about 2.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (3,438,781 versus 1,494,317). Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Viasat for 8 Days on average.
| TNGX | VSAT | |
|---|---|---|
Market Cap | $3.74B | $9.21B |
Volume | 3,438,781 | 1,494,317 |
Sector | Health | Technology |
52-Week High | $32.90 | $89.81 |
52-Week Low | $7.50 | $30.35 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $2.76B | $14.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VSAT trades at $66.9, down 1.12% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $574.96 million in 2025, though revenue grew to $4.52 billion. Recent positive developments include the ViaSat-3 F2 and F3 satellites entering service and a $1 billion joint venture with Space42 to create Equatys for direct-to-device connectivity, signaling growth potential in government and commercial markets.
The outlook is mixed; analyst consensus is a Buy with a $94.29 price target, but near-term profitability challenges and high debt levels pose risks. The stock's investment case hinges on execution of new contracts and satellite deployments driving future earnings growth beyond current losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Viasat
Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →
